FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval-probability scores and historical phase-3 success rates. Worldwide. For biotech-investing and payer agents.

Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents.

Competitive drug pipeline landscape for any disease — full Phase 2/3 trial map, mechanism-of-action coverage, approved drugs, PDUFA calendar, M&A activity, opportunity gaps and investment thesis. Worldwide. For biotech and pharma intelligence agents.

Clinical trial failure analysis for a disease area — why Phase 2/3 trials failed (wrong target, patient population, endpoint, dose, safety), failure taxonomy with percentages, phase-transition success rates and design lessons. Worldwide. For drug developers and biotech investors.

Global clinical trial landscape for any disease — geographic distribution by country across WHO ICTRP registries (US, EU, China, India, Japan, Brazil, Africa and more), regulatory pathways, access gaps and unmet need by region. For CRO, global-pharma and advocacy agents.

Drug mechanism-of-action + molecular target landscape for any disease — targets in active trials, approved agents by MOA, crowded vs novel mechanisms and first-in-class openings, with key publications. Worldwide. For drug-discovery and VC agents.

Recruiting clinical trial finder for a disease or diagnosis — actively recruiting trials with plain-language summaries, eligibility (who can/cannot join), country filter, contacts and how to apply, across 400,000+ ClinicalTrials.gov studies worldwide. For patient-advocacy and provider agents.

Clinical trial pipeline scan for any disease — all active Phase 2/3 trials with trial counts, sponsor landscape, geographic distribution, mechanism breakdown and pipeline density, across 400,000+ trials worldwide. For biotech-investing and pharma agents.

Pharma/biotech company pipeline intelligence — full drug pipeline by phase, therapeutic-area coverage, FDA approval history, partnerships, competitive positioning and investment catalysts for any sponsor. Worldwide. For investor and M&A agents.

Clinical trial deep dive by NCT ID — full trial design, primary/secondary endpoints, enrollment status and countries, sponsor, recruitment criteria, outcomes and publications for any ClinicalTrials.gov study. For research and biotech agents.